GH Research (NASDAQ:GHRS) Stock Rating Raised to Hold at Wall Street Zen

GH Research (NASDAQ:GHRS) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

GHRS has been the topic of several other research reports. Guggenheim boosted their target price on GH Research from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, August 7th. New Street Research set a $65.00 price target on GH Research in a research report on Monday, August 10th. Zacks Research raised shares of GH Research from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research report on Thursday, October 15th. Finally, Stifel Nicolaus set a $38.00 target price on shares of GH Research in a research note on Friday. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, GH Research presently has an average rating of “Moderate Buy” and a consensus target price of $44.36.

GH Research Price Performance

Shares of NASDAQ GHRS opened at $19.10 on Friday. The business’s 50 day moving average is $22.30 and its two-hundred day moving average is $21.64. GH Research has a 1-year low of $12.04 and a 1-year high of $31.44. The stock has a market capitalization of $1.31 billion, a P/E ratio of -19.10 and a beta of 1.31.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Friday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.13. As a group, equities research analysts anticipate that GH Research will post -1.20 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

Several hedge funds have recently bought and sold shares of the business. Troluce Capital Advisors LLC increased its stake in GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after purchasing an additional 617,260 shares during the period. Braidwell LP purchased a new stake in shares of GH Research during the second quarter valued at $5,571,000. Marshall Wace LLP grew its holdings in shares of GH Research by 46.3% in the third quarter. Marshall Wace LLP now owns 68,298 shares of the company’s stock worth $1,604,000 after purchasing an additional 21,601 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of GH Research in the second quarter worth about $495,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of GH Research by 30.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company’s stock worth $432,000 after purchasing an additional 4,106 shares during the last quarter. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.